Marco Davila: Roswell Park Advances CAR T-Cell Research Across 10 ASH 2026 Abstracts
Marco Davila/roswellpark.org

Marco Davila: Roswell Park Advances CAR T-Cell Research Across 10 ASH 2026 Abstracts

Marco Davila, Senior Vice President and Associate Director for Translational Research at Roswell Park Comprehensive Cancer Center, shared on LinkedIn:

“I’m looking forward to American Society of Hematology meeting in New Orleans and sharing 10 abstracts developed with colleagues Roswell Park Comprehensive Cancer Center and collaborating institutions.

As a physician–scientist, the questions that drive this work come directly from caring for people with cancer: How can we make treatments more effective? Reduce complications? Help more patients access them?

Our studies address several parts of that challenge:

  • Developing new cell therapies: A phase I trial of dual-targeted CD19/CD20 CAR T cells and a phase Ib trial-in-progress evaluating transient CD28 blockade during BCMA CAR T-cell therapy. These early-phase approaches focus on safety and feasibility as we work toward better treatment options.
  • Understanding CAR T-cell resistance and toxicity: Studies examining macrophage-mediated immune suppression, age-related differences in CAR T-cell function, and complement activation in neurotoxicity. Understanding these mechanisms may help us design more effective therapies with fewer complications.
  • Making treatment more individualized: Research examining immune age in multiple myeloma and pretransplant biomarkers- including amphiregulin, CXCL9, and GDF15—to better understand differences in outcomes and complications.
  • Expanding access and reducing treatment burden: Work examining geographic access to myeloma CAR T-cell trials and an economic model of outpatient bispecific antibody initiation. The model projects potential reductions in hospital use and costs; prospective evaluation will be needed.

These projects span preclinical research, biomarker studies, economic modeling, and early-phase trials. Each addresses a different step toward improving care for patients and families.

I’m grateful to our presenters – Amritpal Singh, Allan Pavy, Meredith Stone, Rahul Thakur, Ehsan Malek, Alex Niu, Aleksandr Lazaryan, and Malini Surapaneni – and to every coauthor and research team member who made this work possible.

Thank you to our collaborators across Roswell Park, Moffitt Cancer Center, University at Buffalo, and many others.

Above all, thank you to the patients and families who make clinical research possible and keep our work grounded in what matters.

Explore the attached guide for all 10 studies, collaborators, available presentation schedules, and links to the ASH abstracts. I look forward to connecting in New Orleans.”

About ASH 2026

The 68th American Society of Hematology (ASH) Annual Meeting and Exposition will take place on December 12–15, 2026, in New Orleans, Louisiana, bringing together hematology professionals to present research across blood disorders and hematologic malignancies.

The meeting will feature scientific research addressing CAR-T cell therapy, multiple myeloma, cellular immunotherapy, treatment resistance, clinical trial development and patient outcomes. The 2026 scientific abstracts are available online ahead of the congress.

Read more here.”

You can also read: Nepal Introduces Locally Developed CAR-T Cell Therapy for Cancer Patients

Marco Davila: Roswell Park Advances CAR T-Cell Research Across 10 ASH 2026 Abstracts